Benmelstobart Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5388-10mg

Add to Compare

Be the first to review this product

Benmelstobart Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

IgG1 - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

ICH5388 is a research-grade biosimilar of benmelstobart, an anti-PD-L1 monoclonal antibody. It is supplied as an unconjugated, non-therapeutic analog built around the PD-L1 target, intended strictly for research use (RUO) and not for clinical or diagnostic application. Benmelstobart (also known as TQB2450) is a humanized IgG1 antibody that binds programmed death-ligand 1 and blocks its engagement of PD-1, thereby relieving the inhibitory signal that tumors use to evade T-cell attack. This biosimilar reproduces the target specificity of the originator to serve as a reference and control reagent in immuno-oncology workflows. As a human IgG1-kappa format directed against a human antigen, it is well suited to in-vitro and functional characterization rather than routine mouse in-vivo dosing. It is manufactured to a low-endotoxin research grade (<1 EU/mg) and is available in bulk milligram-to-gram quantities, making it appropriate for assay development, binding and neutralization studies, and comparability or benchmarking work where consistent, well-characterized material is required. PD-L1 (programmed death-ligand 1; CD274, UniProt Q9NZQ7) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. It is expressed on antigen-presenting cells, various normal tissues, and is frequently upregulated on tumor cells and within the tumor microenvironment, often driven by interferon-gamma. By binding its receptor PD-1 on activated T cells, PD-L1 delivers an inhibitory signal that dampens T-cell proliferation, cytokine production, and cytotoxic activity, promoting peripheral tolerance. Tumors exploit this axis to escape immune surveillance. PD-L1 also engages CD80 (B7-1). Antibodies that block the PD-L1/PD-1 interaction restore effector T-cell function and underpin a major class of cancer immunotherapies, making PD-L1 a central node in immune-checkpoint research.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.